IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 110 participants.

Also called NCT06466278

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06466278
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06466278. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-01 (actual); primary completion 2026-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion
Acronym
SALVAGE
Condition
Aortic Valve Stenosis
Intervention (Drug)
Icosapent ethyl
Intervention (Drug)
Placebo
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (class: other)

Record details

Record id
cardio:ct-nct06466278
Content hash
881f2a7d9edeb09cff2eac3d50c56960a879a83f3cccfdb2a142229648d80f9d